|1929||Kamejiro Shimomura begins producing over-the-counter medicines in Toyama City, and selling them at pharmacies and drugstores throughout Japan.|
|1954||Takaharu Shimomura establishes Shimomura Yoshindo in Sanno-machi, Toyama City, and begins the contracted manufacture of medicines.|
Shimomura Yoshindo is reorganized and established as a joint-stock company, and relocates to Shinjo-machi, Toyama City.
Takaharu Shimomura assumes presidency of the company.
|1967||A new company factory is constructed.|
|1970||Company name is changed to Yoshindo Inc.|
|1973||Production of Chlorella and other health foods begins.|
Health food manufacturing section is separated from the company and established as Shinwa Pharmaceuticals Inc.
Operations are focused on the contracted manufacture and sale of prescription drugs.
|1979||Begins exporting to Taiwan.|
|1983||Kenzo Shimomura assumes the presidency. Takaharu Shimomura becomes Chairman.|
|1985||Assists operation of Kenyu Pharmaceuaticals Inc., and strengthens sales.|
|1986||The Fuchu factory is constructed.|
|1994||Merges Kenyu Pharmaceuticals Inc.|
|1995||Capital increased to ¥295,760,000.|
New factory in Fuchu-machi completed.
Capital increased to ¥406,960,000.
Land is acquired for factory construction (21,933m2). Total area of company land rises to 31,850m2.
Factory enlarged by 1,988m2. Total floor area rises to 9,888m2.
|2004||Merges YIC Inc., a group of pharmaceutical ingredient manufacturing companies.|
|2006||Research laboratory is completed.|
|2007||The affiliated company Soken Inc. changes their name to Labre Soken, Inc.|
|2009||Capital is reduced to ¥300,000,000.|
|2010||Bulk drug factory completed. Operations begin.|
|2011||Pharmaceutical production factory No. 2 completed. Operations begin.|
AY Pharmaceuticals Co., Ltd. established as a joint venture.
Expands field of business and begins sales of transfusion and dialysis products as well as GE products.
Introduction of new Tokyo office and branch office system.
YL Biologics Ltd. established as a joint venture.
Biosimilar development begins.
Research building No. 2 completed.
|2016||Pharmaceutical production factory No. 5 completed.|
|2016||Kenzo Shimamura, appointed Chairman of the Board. Hiroki Kitamura, appointed President.|